Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Lu AA34893 in Patients With Bipolar Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Current major depressive episode of bipolar I or bipolar II disorder, according to DSM-IV TR~* Moderate to severe depression~* History of at least one documented mania or hypomania episode~* Absence of current mania or hypomania~Exclusion Criteria:~* Any current psychiatric disorder other than bipolar disorder defined in the DSM-IV TR~* Any substance disorder with the previous 6 months~* Use of any psychoactive medication (including mood stabilizers) within 2 weeks before randomisation and during the study~* ECT within 6 months before the study~* Female of childbearing potential and not using adequate contraception~Other protocol-defined inclusion and exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lu AA34893: 4 mg (Type: EXPERIMENTAL): None
- Lu AA34893: 12 mg (Type: EXPERIMENTAL): None
- Lu AA34893: 18 mg (Type: EXPERIMENTAL): None
- Quetiapine fumarate (Type: OTHER): Active reference 300 mg
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).